×

Biotech and Pharmaceuticals Pharmaceuticals

  • Biotech

    Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.

  • Arena Pharmaceuticals

    Vivus announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals to first reach the bulging waistbands of obese Americans.  TheStreet.com reports.

  • Abbott Laboratories

    Option action lit up yesterday in Abbott Laboratories, which has been a solid performer for the last year.

  • AstraZeneca Poaches Genentech Boss From Roche

    AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.

  • Healthcare cost

    Idenix Pharmaceuticals shares fell 10 percent Monday after the U.S. Food and Drug Administration placed a second of the company's experimental hepatitis C drugs on clinical hold due to heart safety concerns. TheStreet.com reports.

  • Eli Lilly & Co. corporate headquarters stand in Indianapolis, Indiana, U.S., on Monday, May 21, 2012.

    A treatment for Alzheimer's disease from drugmaker Eli Lilly yielded promising signs in late-stage research, even though the drug failed to slow mental decline in two separate studies of patients with mild-to-moderate cases of the mind-robbing condition.

  • Merck

    Now is the time to own stocks with big dividends, one analyst says. In health care, that means large cap pharmaceuticals. TheStreet.com reports.

  • Apple Store

    Apple has quietly told its store workers to match discounts on the iPhone 4 and iPhone 4S from approved major retailers and carriers like Sprint Nextel, which is currently offering a $50 break. Apple won’t offer the discounts automatically; customers have to ask.

  • Think you can’t own growth stocks in this market? Think again.

  • bristol_myers_squibb.jpg

    FBI agents arrested Robert Ramnarine, a Bristol-Myers Squibb executive, on Thursday, and criminally charged him with insider trading in call options, court papers show.

  • bristol_myers_squibb.jpg

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • bank_building_200.jpg

    Large regional banks continue to outperform the money center banks, despite the compelling stock price multiples for the largest bank holding companies.

  • Horizon Pharma should hear good news from U.S. regulators Thursday about its rheumatoid arthritis drug Rayos. Full approval of the drug should be in the bag.

  • bristol_myers_squibb.jpg

    Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.

  • pills_prescription_200.jpg

    Biotech earnings kick off tomorrow, with Biogen reporting pre-market. Biotech has been an exciting space to watch with the sector outperforming the major indices.

  • Johnson & Johnson

    Johnson & Johnson reports earnings Tuesday and is always an important read for the quarter.

  • Find out which second-quarter top performer got the most votes.

  • Biotech

    With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.

  • The Public & Private Battle to Fund Cancer Research

    Patrick Kennedy, One Mind for Research co-founder; John Boockvar, Weill Cornell Medical College; and Franklin Berger, PDL BioPharma senior advisor, discuss an initiative calling on private investors to join in and fund the battle against cancer.

  • stethoscope_money_200.jpg

    Despite the flurry of debate surrounding ObamaCare, which the U.S. Supreme Court is set to rule on later this week, two managing directors emphasized the new products that will be emerging from pharmaceutical companies’ pipelines soon.